Pharmacogenomics of CYP3A: considerations for HIV treatment

Author： Lakhman Sukhwinder S Ma Qing Morse Gene D

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.10, Iss.8, 2009-08, pp. : 1323-1339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS1 *

By WRIGHTON STEVEN SCHUETZ ERIN THUMMEL KENNETH SHEN DANNY KORZEKWA KENNETH WATKINS PAUL

Drug Metabolism Reviews, Vol. 32, Iss. 3-4, 2000-10 ,pp. : 339-361

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenomics: implications and considerations for pharmacists

By Brock Tina Penick Valgus John M Smith Scott R Summers Kelly M

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 321-330

Future Medicine

Access to resources Recommend Favorite

Arrhythmia Pharmacogenomics: Methodological Considerations

Current Pharmaceutical Design, Vol. 15, Iss. 32, 2009-11 ,pp. : 3734-3741

Bentham Science Publishers

Access to resources Recommend Favorite

Ethical considerations in clinical pharmacogenomics research

By Issa A.M.

Trends in Pharmacological Sciences, Vol. 21, Iss. 7, 2000-07 ,pp. : 247-249

Elsevier

Access to resources Recommend Favorite

Drug Treatment of Depression in HIV-Positive Patients: Safety Considerations

By Pieper Andrew A.

Drug Safety, Vol. 28, Iss. 9, 2005-01 ,pp. : 753-762

Adis International

Access to resources Recommend Favorite